human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase
liquid chromatography with ultraviolet or fluorescence and on-line circular
dichroism detection. J Chromatogr B Biomed Sci Appl 1997;701:71–80.
Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A,
Greenberg HE, De Lepeleire I, Van Hecken A, De Schepper PJ, Ebel DL, Schwartz
JI, Rodrigues AD.In vitrometabolism of celecoxib, a cyclooxygenase-2 inhibitor, by
allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation
with CYP2C9 genotype andin vivopharmacokinetics. Pharmacogenetics 2001;11:
223–235.
Tracy TS.Atypical enzyme kinetics: their effect onin vitro–in vivopharmacokinetic
predictions and drug interactions. Curr Drug Metab 2003;4:341–346.
Wilkinson GR, Shand DG.Commentary: a physiological approach to hepatic drug
clearance. Clin Pharmacol Ther 1975;18:377–390.
Winkler K, Keiding S, Tygstrup N.The liver. In: Paumgartner G, Preisig R. editors.
Quantitative Aspects of Structure and Function. Basel: S Karger; 1973. p 144–155.
Yamamoto T, Hagima N, Nakamura M, Kohno Y, Nagata K, Yamazoe Y. Differences
in cytochrome P450 forms involved in the metabolism ofN,N-dipropyl-2-[4-methoxy-
3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100), a novel sigma
ligand, in human liver and intestine. Drug Metab Dispos 2003;31:60–66.
Zhang ZY, Kaminsky LS. Characterization of human cytochromes P450 involved in
theophylline 8-hydroxylation. Biochem Pharmacol 1995;50:205–211.
Zhang ZY, King BM, Mollova NN, Wong YN.In vitrointeractions between a potential
muscle relaxant E2101 and human cytochromes P450. Drug Metab Dispos
2002;30:805–813.
Zhang ZY, Wong YN. Enzyme kinetics for clinically relevant CYP inhibition. Curr
Drug Metab 2005;6:241–257.
Zhao SX, Forman D, Wallace N, Smith BJ, Meyer D, Kazolias D, Gao F, Soglia J,
Cole M, Nettleton D.Simple strategies for reducing sample loads inin vitrometabolic
stability high-throughput screening experiments: a comparison between traditional,
two-time-point and pooled sample analyses. J Pharm Sci 2005;94:38–45.
Ziegler DM. An overview of the mechanism, substrate specificities, and structure of
FMOs. Drug Metab Rev 2002;34:503–511.
Zuegge J, Schneider G, Coassolo P, Lave T. Prediction of hepatic metabolic clearance:
comparison and assessment of prediction models. Clin Pharmacokinet 2001;40:553–
563.
446 DETERMINATION OF METABOLIC RATES AND ENZYME KINETICS